Business Context and Reporting Period
Company: Novavax, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: Novavax is a clinical-stage biopharmaceutical company focused on developing vaccines using its proprietary Virus-Like Particle (VLP) platform and disposable manufacturing technology. The company transitioned from a specialty pharmaceutical business (Estrasorb) to a vaccine-focused entity in 2005. Key product candidates include vaccines for pandemic influenza (H5N1), seasonal influenza, Varicella Zoster (Shingles), and Respiratory Syncytial Virus (RSV).
Key Financial Metrics
| Metric | 2008 | 2007 |
|---|---|---|
| Total Revenues | $1.1 million | $1.5 million |
| Net Loss | $(36.0) million | $(34.8) million |
| Loss from Continuing Operations | $(36.3) million | $(28.6) million |
| Income from Discontinued Operations | $0.3 million | $(6.2) million |
| Research & Development Expenses | $24.3 million | $17.6 million |
| Cash and Cash Equivalents | $26.9 million | $4.4 million |
| Short-Term Investments (Fair Value) | $7.0 million | $9.2 million |
| Working Capital | $7.4 million | $42.8 million |
| Convertible Notes Outstanding | $22.0 million | $22.0 million |
Note: The company recorded a $1.2 million impairment loss on auction rate securities in 2008. Discontinued operations relate to the sale of Estrasorb assets to Graceway Pharmaceuticals.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 30% to $1.1 million, primarily due to a 31% drop in contract research and development revenue following the completion of a government contract.
- Increased R&D Spend: Research and development expenses rose 38% to $24.3 million, driven by expanded clinical trials for influenza vaccines and license fees paid to Wyeth.
- Discontinued Operations Turnaround: The company reported a net income of $0.3 million from discontinued operations in 2008, compared to a loss of $6.2 million in 2007, following the sale of Estrasorb assets and completion of supply obligations.
- Investment Impairment: A $1.2 million other-than-temporary impairment charge was recorded on auction rate securities due to credit market illiquidity.
- Working Capital Contraction: Working capital decreased significantly from $42.8 million to $7.4 million, largely due to the reclassification of convertible notes to current liabilities and operating losses.
Guidance, Outlook, and Risks
Outlook and Strategy: Novavax intends to seek collaborative partners for its pandemic and seasonal influenza vaccines upon completion of Phase II studies (expected by end of 2009). The company plans to continue preclinical development of RSV and Varicella Zoster vaccines. Management believes current cash resources, combined with anticipated proceeds from a stock sale to Cadila Pharmaceuticals (see below), are sufficient to operate for at least the next 12 months.
Material Risks and Contingencies:
- Liquidity and Debt Maturity: $22.0 million in senior convertible notes mature on July 15, 2009. The company must pay at least $11.0 million in cash unless the notes are converted, redeemed, or amended. Conversion is contingent on the stock price and NASDAQ listing status.
- Capital Markets: The company faces challenges raising capital due to volatile market conditions and a low stock price. Future equity offerings would be significantly dilutive.
- Auction Rate Securities: $8.2 million face value of auction rate securities are illiquid. While valued at $7.0 million, the company may be unable to liquidate them at acceptable prices.
- Delisting Risk: The company's stock price has fallen below the $1.00 minimum bid price required by NASDAQ. Failure to regain compliance could result in delisting, which would restrict the ability to convert debt into equity.
- Related Party Notes: Two former directors owe the company approximately $1.6 million in notes. Collectability is uncertain, and the notes are secured by pledged shares.
Important Facts for Investor Verification
- Convertible Note Maturity: Verify the company's ability to raise the minimum $11.0 million cash required to satisfy the July 15, 2009, debt maturity.
- Cadila Transaction: Confirm the closing of the March 31, 2009, stock purchase agreement with Cadila Pharmaceuticals (12.5 million shares at $0.88/share) and the receipt of ~$10.65 million in net proceeds.
- NASDAQ Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid requirement to avoid delisting, which is a condition for debt conversion.
- Liquidity of Investments: Assess the realizable value of the $7.0 million in auction rate securities and the potential for further impairment.
- Clinical Trial Progress: Track the results of the Phase II seasonal influenza trials and the initiation of further pandemic influenza trials with a partner.